insights_auto
EVT neden yükseldi? 5,00%?
Daha Ayrıntılı Bilgichevron_right
EVT:ETR
Evotec SE
€2,86
arrow_upward
+5,00%(+0,14) 1G
21 Eki, 17:37:21 GMT+2 · EUR
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoEVT ile ilgili en önemli analizler oluşturuluyor...
Açık
€2,70
Yüksek
€2,86
Düşük
€2,69
Piy. değ.
498,74 Mn
Ort. hacim
1,21 Mn
İşlem Hacmi
0,00
52 haftalık en yüksek
€7,30
52 haftalık en düşük
€2,41
HBK
-€1,11
Tedavüldeki hisse senedi sayısı
177,91 Mn
Çalışan sayısı
4 B
Açık
€2,70
Yüksek
€2,86
Düşük
€2,69
Piy. değ.
498,74 Mn
Ort. hacim
1,21 Mn
İşlem Hacmi
0,00
52 haftalık en yüksek
€7,30
52 haftalık en düşük
€2,41
HBK
-€1,11
Tedavüldeki hisse senedi sayısı
177,91 Mn
Çalışan sayısı
4 B
Haberler
Web kaynaklarından ve haber iş ortaklarından
AD HOC NEWS
·
6 saat önce
Evotec stock: RBC keeps EUR 10.00 target for Evotec stock
AD HOC NEWS
·
13 saat önce
Evotec appoints Joanna Holbrook as chief scientific officer. Evotec stock gains 1.47 percent
AD HOC NEWS
·
16 saat önce
Evotec stock at EUR 2.77 ahead of the Xetra open: drug group rises 1.84 percent
AD HOC NEWS
·
17 saat önce
Evotec's Earnings Beat Is Real — the Profit Is Not
Profil
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE hakkında